Donatienne Taylor
Publication Activity (10 Years)
Years Active: 2022-2023
Publications (10 Years): 3
Publications (10 Years): 3
Publications
- Laurence Buisseret, Delphine Loirat, Philippe Aftimos, Christian Maurer, Kevin Punie, Véronique Debien, Paulus Kristanto, Daniel Eiger, Anthony Goncalves, François Ghiringhelli, Donatienne Taylor, Florent Clatot, Tom Van den Mooter, Jean-Marc Ferrero, Hervé Bonnefoi, Jean-Luc Canon, Fran Ois P Duhoux, Laura Mansi, Renaud Poncin, Philippe Barthélémy, Nicolas Isambert, Zoë Denis, Xavier Catteau, Roberto Salgado, Elisa Agostinetto, Evandro de Azambuja, Françoise Rothé, Ligia Craciun, David Venet, Emanuela Romano, John Stagg, Marianne Paesmans, Denis Larsimont, Christos Sotiriou, Michail Ignatiadis, Martine J Piccart
- Laurence Buisseret, Delphine Loirat, Philippe Aftimos, Christian Maurer, Kevin Punie, Véronique Debien, Paulus Kristanto, Daniel Eiger, Anthony Goncalves, François Ghiringhelli, Donatienne Taylor, Florent Clatot, Tom Van den Mooter, Jean-Marc Ferrero, Hervé Bonnefoi, Jean-Luc Canon, Fran Ois P Duhoux, Laura Mansi, Renaud Poncin, Philippe Barthélémy, Nicolas Isambert, Zoë Denis, Xavier Catteau, Roberto Salgado, Elisa Agostinetto, Evandro de Azambuja, Françoise Rothé, Ligia Craciun, David Venet, Emanuela Romano, John Stagg, Marianne Paesmans, Denis Larsimont, Christos Sotiriou, Michail Ignatiadis, Martine J Piccart
- Francois-Clement Bidard, Virginia G Kaklamani, Patrick Neven, Guillermo Streich, Alberto J Montero, Frédéric Forget, Marie-Ange Mouret-Reynier, Joo Hyuk Sohn, Donatienne Taylor, Kathleen K Harnden, Hung T Khong, Judit Kocsis, Florence Dalenc, Patrick M Dillon, Sunil Babu, Simon H Waters, Ines Deleu, José A García Sáenz, Emilio Bria, Marina Elena Cazzaniga, Janice Lu, Philippe Aftimos, Javier Cortes, Shubin Liu, Giulia Tonini, Dirk Laurent, Nassir Habboubi, Maureen G Conlan, Aditya BardiaElacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (28) (2022)